Paul, Weiss

Krishna Veeraraghavan

Deals
4
Latest
Jun 2026
Most deals in
Biotech

Firm

Deals by year
Krishna Veeraraghavan: deals by year0123420252026 YTD: 4 M&A42026 YTDM&AEquity raisings

Often works with

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deals Krishna Veeraraghavan was named on, most recent first
Jun 2026 Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program Sangamo TherapeuticsEli Lilly and CompanyAsset saleLegal adviser to Eli Lilly and Company (acquirer)Completed–Biotech+1Eli Lilly and Company acquisition of Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program
Mar 2026 Ouro Medicines –GileadAcquisitionLegal adviser to GalapagosAnnounced1,675.0Biotech+1Gilead acquisition of Ouro Medicines
Feb 2026 35Pharma –GSKAcquisitionLegal adviser to GSK (acquirer)Announced950.0Biotech+1GSK acquisition of 35Pharma
Feb 2026 Orna Therapeutics –Eli Lilly and CompanyAcquisitionLegal adviser to Eli Lilly and Company (acquirer)Announced2,400.0Biotech+1Eli Lilly and Company acquisition of Orna Therapeutics

Deals where Krishna Veeraraghavan is named on the firm's deal team, by the firm or the press.

Suggest a correction

A missing deal, a wrong firm, a move between firms, or two different people shown as one. A link to a public source helps.